Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Capital Expenditures (2016 - 2019)

Outlook Therapeutics (OTLK) has disclosed Capital Expenditures for 5 consecutive years, with $1.0 as the latest value for Q3 2019.

  • On a quarterly basis, Capital Expenditures fell 100.0% to $1.0 in Q3 2019 year-over-year; TTM through Sep 2019 was $437307.0, a 84.28% decrease, with the full-year FY2019 number at $437307.0, down 84.28% from a year prior.
  • Capital Expenditures was $1.0 for Q3 2019 at Outlook Therapeutics, up from -$657960.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $3.5 million in Q2 2015 to a low of -$1.0 million in Q1 2018.
  • A 5-year average of $632910.3 and a median of $282422.0 in 2016 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 9566.88% in 2018; the steepest drop was 1415.02% in 2018.
  • Outlook Therapeutics' Capital Expenditures stood at $364242.0 in 2015, then crashed by 59.27% to $148362.0 in 2016, then surged by 624.68% to $1.1 million in 2017, then plummeted by 78.01% to $236433.0 in 2018, then plummeted by 100.0% to $1.0 in 2019.
  • Per Business Quant, the three most recent readings for OTLK's Capital Expenditures are $1.0 (Q3 2019), -$657960.0 (Q2 2019), and $858833.0 (Q1 2019).